The C-TRACT Trial is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and governed by the terms of grants UG3HL138325 (to Dr. Suresh Vedantham from Washington University in St. Louis, MO), U24HL13783 (to Dr. Clive Kearon at McMaster University in Hamilton, Ontario), and subsequent NIH grant awards. The C-TRACT Trial is registered at under registration number NCT03250247. The off-label use of stents is covered under Investigational Device Exemption (IDE) G170161 from the Food and Drug Administration (FDA).

The NHLBI Project Officer for the C-TRACT Trial is Dr. Andrei Kindzelski. The NHLBI’s commitment to DVT research is illustrated by its strong support of the ATTRACT and C-TRACT Trials and by its leadership in developing key elements of the federal response to this public health challenge, including the 2008 Surgeon General’s Call to Action on DVT and PE.

The National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health (NIH), provides global leadership for research, training, and education programs to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. The NIH, a part of the United States Department of Health and Human Services, is the primary Federal agency for conducting and supporting medical research. Helping to lead the way toward important medical discoveries that improve people’s health and save lives, NIH scientists investigate ways to prevent disease as well as the causes, treatments, and even cures for common and rare diseases.